Ediz Cosar to Pancreatic Neoplasms
This is a "connection" page, showing publications Ediz Cosar has written about Pancreatic Neoplasms.
Connection Strength
0.382
-
Sakhdari A, Moghaddam PA, Pejchal M, Cosar EF, Hutchinson L. Sequential molecular and cytologic analyses provides a complementary approach to the diagnosis of pancreatic cystic lesions: a decade of clinical practice. J Am Soc Cytopathol. 2020 Jan - Feb; 9(1):38-44.
Score: 0.132
-
Sakhdari A, Hutchinson L, Vaskas N, Scott M, Cosar EF, Al-Turkmani R. Routine Analysis of Lipase in Cyst Fluid Is Unnecessary and Does Not Help Discriminate Between Nonneoplastic and Neoplastic Cystic Pancreatic Lesions. Pancreas. 2017 Mar; 46(3):e25-e27.
Score: 0.110
-
Morgan TK, Hardiman K, Corless CL, White SL, Bonnah R, Van de Vrugt H, Sheppard BC, Grompe M, Cosar EF, Streeter PR. Human pancreatic cancer fusion 2 (HPC2) 1-B3: a novel monoclonal antibody to screen for pancreatic ductal dysplasia. Cancer Cytopathol. 2013 Jan; 121(1):37-46.
Score: 0.080
-
Yantiss RK, Cosar E, Fischer AH. Use of IMP3 in identification of carcinoma in fine needle aspiration biopsies of pancreas. Acta Cytol. 2008 Mar-Apr; 52(2):133-8.
Score: 0.059